EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--July 18, 2006--SurModics, Inc. (Nasdaq:SRDX - News), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today an expanded relationship with DIARECT AG. Under this new agreement, SurModics will distribute DIARECT’s recombinant autoimmune antigens to in vitro diagnostics (IVD) customers on an exclusive basis in North America and on a non-exclusive basis in Japan.
